Clinical and economic outcomes of medication therapy management services: the Minnesota experience.

OBJECTIVES To (1) provide medication therapy management (MTM) services to patients, (2) measure the clinical effects associated with the provision of MTM services, (3) measure the percent of patients achieving Healthcare Effectiveness Data and Information Set (HEDIS) goals for hypertension and hyperlipidemia in the MTM services intervention group in relationship to a comparison group who did not receive MTM services, and (4) compare patients' total health expenditures for the year before and after receiving MTM services. DESIGN Prospective study. SETTING Six ambulatory clinics in Minnesota from August 1, 2001, to July 31, 2002. PATIENTS 285 intervention group patients with at least 1 of 12 medical conditions using prestudy health claims; 126 comparison group patients with hypertension and 126 patients with hyperlipidemia were selected among 9 clinics without MTM services for HEDIS analysis. INTERVENTION MTM services provided by pharmacists to BlueCross BlueShield health plan beneficiaries in collaboration with primary care providers. MAIN OUTCOME MEASURES Drug therapy problems resolved; percentage of patients' goals of therapy achieved and meeting HEDIS measures for hypertension and hypercholesterolemia. Total health expenditures per person were measured for a 1-year period before and after enrolling patients in MTM services. RESULTS 637 drug therapy problems were resolved among 285 intervention patients, and the percentage of patients' goals of therapy achieved increased from 76% to 90%. HEDIS measures improved in the intervention group compared with the comparison group for hypertension (71% versus 59%) and cholesterol management (52% versus 30%). Total health expenditures decreased from $11,965 to $8,197 per person (n = 186, P < 0.0001). The reduction in total annual health expenditures exceeded the cost of providing MTM services by more than 12 to 1. CONCLUSION Patients receiving face-to-face MTM services provided by pharmacists in collaboration with prescribers experienced improved clinical outcomes and lower total health expenditures. Clinical outcomes of MTM services have chronic care improvement and value-based purchasing implications, and economic outcomes support inclusion of MTM services in health plan design.

[1]  Brian T. Austin,et al.  Organizing care for patients with chronic illness. , 1996, The Milbank quarterly.

[2]  Hoangmai H Pham,et al.  Care patterns in Medicare and their implications for pay for performance. , 2007, The New England journal of medicine.

[3]  B. Arondekar,et al.  Evidence of the Economic Benefit of Clinical Pharmacy Services: 1996–2000 , 2003, Pharmacotherapy.

[4]  H. Hatoum,et al.  1993 Bibliography: A 32-Year Literature Review on the Value and Acceptance of Ambulatory Care Provided by Pharmacists , 1993, The Annals of pharmacotherapy.

[5]  J. Schaefer,et al.  Collaborative Management of Chronic Illness , 1997, Annals of Internal Medicine.

[6]  D. Bates,et al.  Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.

[7]  R. Mikeal,et al.  Quality of pharmaceutical care in hospitals. , 1975, American journal of hospital pharmacy.

[8]  B. Bluml.  Definition of medication therapy management: development of professionwide consensus. , 2005, Journal of the American Pharmacists Association : JAPhA.

[9]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness. , 2002, JAMA.

[10]  Michael J. Peters,et al.  Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. , 2003, Archives of internal medicine.

[11]  Effects of collaborative drug therapy management on patients' perceptions of care and health-related quality of life. , 2006, Research in social & administrative pharmacy : RSAP.

[12]  Fang-Shu Ou,et al.  Pay for performance, quality of care, and outcomes in acute myocardial infarction. , 2007, JAMA.

[13]  K. Teo,et al.  A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). , 2002, Archives of internal medicine.

[14]  M. Porter,et al.  Redefining Health Care: Creating Value-based Competition on Results , 2006 .

[15]  W. Smith,et al.  Levels of pharmaceutical care: a theoretical model. , 1991, American journal of hospital pharmacy.

[16]  B. Isetts,et al.  CPT code-change proposal: national data on pharmacists' medication therapy management services. , 2007, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[17]  C. Catizone,et al.  An Eleven-Year Review of the Pharmacy Literature: Documentation of the Value and Acceptance of Clinical Pharmacy , 1986, Drug intelligence & clinical pharmacy.

[18]  L. Strand,et al.  Pharmaceutical Care Practice: The Clinician's Guide , 2004 .

[19]  B. Isetts,et al.  Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. , 2003, Archives of internal medicine.

[20]  L. Bero,et al.  Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. , 2000, The Cochrane database of systematic reviews.

[21]  L. Strand,et al.  Pharmaceutical Care Practice , 1998 .

[22]  G. Schumock,et al.  Economic Evaluations of Clinical Pharmacy Services—1988–1995 , 1996, Pharmacotherapy.

[23]  E H Wagner,et al.  Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.

[24]  E H Wagner,et al.  Quality improvement in chronic illness care: a collaborative approach. , 2001, The Joint Commission journal on quality improvement.

[25]  R. Slaughter,et al.  Pharmacists' Ability to Influence Outcomes of Hypertension Therapy , 1997, Pharmacotherapy.

[26]  C. E. Webb,et al.  Collaborative Drug Therapy Management by Pharmacists—2003 , 2003, Pharmacotherapy.

[27]  Todd D. Sorensen,et al.  Use of a student-driven, university-based Pharmaceutical Care Clinic to define the highest standards of patient care , 1999 .

[28]  M G Amato,et al.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.

[29]  F. Blicke,et al.  Analogs of (+/-)-epinephrine. , 1956, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[30]  J L Bootman,et al.  Drug-related morbidity and mortality and the economic impact of pharmaceutical care. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[31]  J. Mckenney,et al.  Pharmaceutical care services and results in project ImPACT: hyperlipidemia. , 2000, Journal of the American Pharmaceutical Association.

[32]  V. Hasselblad,et al.  Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. , 1999, Archives of internal medicine.

[33]  D. Christensen,et al.  The asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. , 2003, Journal of the American Pharmaceutical Association.

[34]  C. Pugh,et al.  Implementation of Pharmaceutical Care Services for Patients with Hyperlipidemias by Independent Community Pharmacy Practitioners , 1997, The Annals of pharmacotherapy.

[35]  D. Christensen,et al.  The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. , 2012, Journal of the American Pharmaceutical Association.